O.M. STANISHEVSKAYA, V.V. CHERNYKH, A.N. TRUNOV, V.I. BRATKO, G.V. BRATKO, M.A. MALINOVSKAYA, I.Yu. EFREMOVA

Novosibirsk Branch of the S. Fyodorov Eye Microsurgery Federal State Institution, 10 Kolkhitskaya Str., Novosibirsk, Russian Federation, 630071

 Stanishevskaya O.M. — ophthalmologist of the 4^th Ophthalmological Department e-mail: [email protected]

Chernykh V.V. — D. Med. Sc., Professor, Director, tel. (383) 341-01-55, e-mail: [email protected]

Trunov A.N. — D. Med. Sc., Professor, Head of the Scientific Department, tel. (383) 340-37-14, e-mail: [email protected]

Bratko V.I. — D. Med. Sc., Head of the Department of efferent therapy, tel. (383) 340-37-14, e-mail: [email protected]

Bratko G.V. — Cand. Med. Sc., ophthalmologist and senior research of the Scientific Department, e-mail: [email protected]

Malinovskaya M.A. — Head of the 4^th Ophthalmological Department, e-mail: [email protected]

Efremova I.Yu. — Ophthalmologist of the 4^th Ophthalmological Department, e-mail: [email protected]

The article presents the results of treatment of patients with central serous chorioretinopathy (CSC) using subthreshold microimpulse laser treatment (SMLT) of 577 nm as monotherapy and in combination with injections of enriched platelet autoplasma. The effectiveness of the use of SMLT of 577 nm with injections of an autologous plasma into the region of the pterygoid fossa as compared with SMLT monotherapy in the treatment of CSC was asessed. The issues of modern treatment of CSC are considered. Patients in the 1^st group received SMLT monotherapy of 577 nm. In the combined treatment, SMLT with a wavelength of 577 nm was applied first. The second stage after the laser exposure to the patient was performed by injecting an autologous plasma into the region of the pterygoid fossa in the amount of 3 pieces, the next day at a frequency of 72 to 96 hours. The selection of laser radiation parameters in each specific case is individual, taking into account the edema height and the degree of pigmentation of the fundus, as well as the transparency of optical media. The final result was evaluated after one month. Mean visual acuity before treatment in group 1: up to — 0,69D, after — 0,8D, height of macular edema to SMLT 349 nm and after — 301 nm. In group 2, the average visual acuity before SMLT + TA 0.79D, after 0.9 D, the height of the macular edema up to — 401 nm after treatment of 258 nm. According to the dynamics and results of treatment, it is shown that the effectiveness of 5757 nm (Quantel Medical) is favorable. Considering the safety of the 577 nm SMLT technique, this type of laser surgical treatment can be used for diapede leakage and for liqueur in the paramacular region. Combined treatment with pterygopalatine injections of autologous plasma in comparison with SMLT 577 nm in monotherapy gives a faster result in the dynamics of decrease in macular edema and increase of photosensitivity.

Key words: subthreshold microimpulse laser treatment (SMLT), central serous chorioretinopathy (CSC), macular edema in central serous chorioretinopathy (ME in CSC), platelet autoplasma (PA).

REFERENCES

1. Mutikov I.V., Mazunin I.Yu. Nash opyt v lechenii tsentral’noy seroznoy khorioretinopatii (TsSKhRP) s yukstasubfoveolyarnoy lokalizatsiey tochki fil’tratsii s pomoshch’yu subporogovogo mikroimpul’snogo infrakrasnogo lazernogo vozdeystviya (SMILV) [Our experience in the treatment of central serous chorioretinopathy (CSHRP) with juxtasubfoveolar localization of the filtration point with the help of subthreshold micropulse infrared laser (SMILV)]. IV Vserossiyskiy seminar “kruglyy stol” — “Makula-2010”: tezisy dokladov. Rostov on Don, 2010. Pp. 452-453.
2. Shchuko A.G., Zlobina A.N., Yur’eva T.N. Etiopathogenetic approaches to diagnosis and treatment of acute and chronic central serous chorioretinopathy: A review of the literature. Oftal’mologiya, 2013, no. 2, pp. 14-19 (in Russ.).
3. Carvalho-Recchia C.A., Yannuzzi L.A., Negrao S. et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology, 2002, vol. 109, pp. 1834-1837.
4. Gatsu M.V. Effektivnost’ fotodinamicheskoy terapii pri khronicheskikh formakh tsentral’noy seroznoy khorioretinopatiii. Prichiny neudach [The effectiveness of photodynamic therapy in chronic forms of central serous chorioretinopathy. Reasons for failure]. IV Vserossiyskiy seminar “kruglyy stol” — “Makula-2010”: tezisy dokladov. Rostov on Don, 2014. Pp. 139-155.
5. Balles M.W., Puliafito C.A., Amico D.J. et al. Semiconductor diode laser photocoagulation in retinal vascular disease. Ophthalmology, 1990, vol. 97, pp. 1553-1561.
6. Balashevich L.I. Sozdanie i izuchenie effektivnosti primeneniya argonovogo i diodnogo lazerov pri patologii glaznogo dna: avtoref. dis. … d-ra med. nauk [Creation and study of the effectiveness of the use of argon and diode lasers in the pathology of the fundus. Synopsis of dis. Dr med. sci]. Saint Petersburg, 1996. 42 p.
7. Mutikov I.V., Mazunin I.Yu. Nash opyt v lechenii tsentral’noy seroznoy khorioretinopatii (TsSKhRP) s yukstasubfoveolyarnoy lokalizatsiey tochki fil’tratsii s pomoshch’yu subporogovogo mikroimpul’snogo infrakrasnogo lazernogo vozdeystviya (SMILV) [Our experience in the treatment of central serous chorioretinopathy (CSHRP) with juxtasubfoveolar localization of the filtration point with the help of subthreshold micropulse infrared laser (SMILV)]. IV Vserossiyskiy seminar “kruglyy stol” — “Makula-2010”: tezisy dokladov. Rosto on Don, 2010. Pp. 452-453.
8. Francisco Arnalich, Alejandra E. Rodriguez, Avaro Luque — Rio, Jorge L. Alio. Solid Platenet Rich Plasma in Corneal Surgery. Ophthalmol Ther., 2016, June; 5(1):31-45.
9. Sanchez A.R., Sheridan P.J., Kupp L.I., Is platelet-rich plasma the perfect enhancement factor. A current review. Int J Oral Maxillofac Implants, 2003;18:93-103.
10. Figueroa M.S., Govetto A., Arriba-Palomero Pd. Short-term results of platelet-rich plasma as adjuvant to 23-G vitrectomy in the treatment of high myopic macular holes. Eur. J. Ophthalmol., 2016, Aug 4; 26(5):491-6. doi: 10.5301/ejo.5000729.
11. Alio J.L., Abad M., Artola A., Rodriquez-Prats J.L., Pastor S., Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology, 2007, Jul; 114(7):1286-1293.